Divis Laboratories Ltd Share Price
(DIVISLAB)
₹5640
as on 04:01PM, 17 Apr 2025
Divis' Laboratories Performance
Day's Low
Day's High
₹5,596Day's Price Range₹5,79852 Week's Low
52 Week's High
₹3,64152-Week Price Range₹6,285.45
| Returns % | |
| 1 Month Return | -2.3 % |
| 3 Month Return | -6.01 % |
| 1 Year Return | + 52.07 % |
| Market Stats | |
| Previous Close | ₹5,754.00 |
| Open | ₹5,750.00 |
| Volume | 5.32L |
| Upper Circuit | ₹6,329.00 |
| Lower Circuit | ₹5,179.00 |
| Market Cap | ₹1,49,724.28Cr |
Divis' Laboratories Fundamentals
P/E Ratio
72.45
PEG Ratio
2.81
Market Cap
₹1,49,724.28 Cr
P/B Ratio
6.75
EPS
60.38
Dividend Yield
0.87
Sector
Pharmaceuticals
ROE
12.04
Mutual Fund Holdings of Divis' Laboratories
Divis' Laboratories Analyst Rating
based on 29 analysts
35.71%
Buy
21.43%
Hold
42.86%
Sell
Based on 29 analysts offering long term price targets for Divis' Laboratories. An average target of ₹5913.76
Source: S&P Global Market Intelligence
Divis' Laboratories Share analysis
Divis' Laboratories price forecast by 29 analysts
Upside of4.85%
High
₹7400
Target
₹5913.76
Low
₹4118
Divis' Laboratories target price ₹5913.76, a slight upside of 4.85% compared to current price of ₹5640. According to 29 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis' Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:63.52%
Forecast
Actual
Including amortisation and stock based compensations
Divis' Laboratories EPS growth forecast
EPS estimate Q1, FY2027:106.18%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Divis Laboratories Ltd
Divis Laboratories Shares Drop Amid Tariff Concerns - 04 Apr, 2025
Divis Laboratories shares fell over 6% to ₹5,410.60 following U.S. President Trump's comments on potential tariffs on pharmaceutical imports, raising investor concerns. The stock's decline reflects fears of increased manufacturing costs and policy risks for companies exporting to the U.S.Divis Laboratories Shares Rise on Positive Recommendations - 03 Apr, 2025
Divis Laboratories shares saw a 1.90% increase following tariff exemptions for pharmaceuticals. SBI Securities recommends buying with targets of Rs 5,830 and Rs 5,900.Divis Labs Positioned for Growth Amid Industry Challenges - 01 Apr, 2025
Divis Laboratories is poised for continued success with a strong growth trajectory, debt-free balance sheet, and strategic expansions. The ramp-up of its Kakinada facility is expected to enhance margins, with a price target of Rs 7,008 anticipated in 8 to 10 months.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Divis Laboratories Excluded from Index, Faces Volatility - 28 Mar, 2025
Divis Laboratories has faced a volatile market since its exclusion from the index in September 2024, as noted in recent reports.Divis Laboratories Reports Strong Growth and Expansion - 14 Mar, 2025
Divis Laboratories' stock rose 1.6% to Rs. 5,756.55. The company reported a 25% revenue increase to Rs. 2,319 crores and a 64.5% net profit growth to Rs. 589 crores in Q3 FY25. Additionally, it is developing a significant manufacturing facility in Kakinada, Andhra Pradesh.Divis Laboratories Stock Target and Growth Outlook - 07 Mar, 2025
Divis Laboratories Ltd has a price target of Rs 6,850, indicating a 24% upside. The brokerage anticipates over 25% earnings growth in the next two years, driven by new capacity and GLP-1 as potential upside risks.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 430.0 Cr → 589.0 Cr (in ₹), with an average increase of 14.6% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 17.25% to 17.99% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 year, DIVISLAB stock has moved up by 55.1%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.89% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.9% return, outperforming this stock by 98.7%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 11.92% to 11.89% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.80% to 9.59% in Dec 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.44K Cr → 2.40K Cr (in ₹), with an average decrease of 1.8% per quarter
Divis' Laboratories News
Tata Power Solarizes 230 Critical Public Infrastructure Across Maharashtra
Tata Power has accelerated Maharashtras green energy transition by solarizing over 230 critical public infrastructure sites across the state, supporting the governments initiative to promote solar power, a senior official announced on Thursday. The installations, totalling approximately 107 MW in clean energy capacity, include 100 hospitals (3.6 MW), 64 schools (2 MW), and 72 government and institutional buildings (100 MW) distributed across key districts. Through these efforts, Tata Powers installations are offsetting 1.3 lakh tonnes of CO₂ emissions, a reduction considered equivalent to planting 20 lakh trees, the official said. The solarisation of critical public facilities is in line with Tata Powers commitment to the clean energy transition and a community-focused approach to sustainability. The company is reducing energy costs, increasing energy reliability, and supporting a decrease in carbon emissions across Maharashtra. Tata Power continues its collaboration with various government bodies to facilitate the delivery of scalable renewable energy solutions that further the states green development objectives. Tata Power has achieved more than 1.5 lakh solar installations nationally, confirming its leadership as Indias No. 1 rooftop solar provider. Its total installed rooftop capacity is nearly 3 GW. The Tata Power Solaroof business operates in 700+ cities, offering consumers up to 80% savings on electricity bills and a 25-year warranty on solar modules. The business is supported by a network of 575+ channel partners across more than 300 cities, ensuring effective last-mile service and delivery. Recently, Tata Power had announced that more than 50,000 consumers have opted for green power in its Mumbai distribution network. This led to an annualised sale of 343 Million Units of green power and helped reduce carbon emissions by 251 Kilotons. The MERC had recently reduced the additional tariff for green power from 66 paise per unit to 25 paise per unit. Tata Power supplies power to over 7.5 lakh consumers in the city.17 Apr, 2025 11:14 PMTata Power Solarizes 230 Institutions in Maharashtra - 107 MW Clean Energy
Tata Power has installed solar panels at over 230 public institutions in Maharashtra, generating 107 MW of clean energy and offsetting 1.3 lakh tonnes of CO2 emissions. The solar installations cover 100 hospitals (3.6 MW), 64 schools (2 MW), and 72 government and institutional buildings (100 MW) across key districts, Tata Power said in a statement. These installations are offsetting 1.3 lakh tonnes of CO2 emissions, equivalent to planting 20 lakh trees.17 Apr, 2025 07:27 PMStock Market Close Highlights: Sensex Vaults 1,578 Points
Tata Powers subsidiary Tata Power Renewable Energy has signed a power purchase agreement (PPA) with state-run NTPC to set up a 200 megawatt (MW) Firm and Dispatchable Renewable Energy Project. The project is expected to be valued at around ₹4,500 crore and is expected to be finished within 24 months.15 Apr, 2025 03:46 PMDivis' Laboratories Financials
Divis' Laboratories Index Inclusions
Divis' Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | 0.00 | |
| Foreign Institutions | 17.99% | 4.26 | |
| Mutual Funds | 11.89% | ||
| Retail Investors | 9.59% | ||
| Others | 8.65% |
Divis' Laboratories Key Indicators
Divis' Laboratories Valuation
Divis' Laboratories in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (53.02x)
April 17, 2025
Today (72.45x)
April 17, 2025
Highest (90.48x)
December 4, 2024
Divis' Laboratories Earnings and Dividends
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 64.53% since last year same period to ₹589Cr in the Q3 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 15.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Divis Laboratories Ltd has declared dividend of ₹30 - translating a dividend yield of 0.53%.
Read More about Dividends
Divis' Laboratories Technicals Summary
Bearish
Neutral
Bullish
Divis Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
Divis' Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,49,724.28 Cr | 28.15% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,152.27 Cr | 35.85% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹39,775.88 Cr | -1.49% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,879.80 Cr | -4.07% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,22,370.15 Cr | 31.77% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Divis' Laboratories
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Revenue: ₹2,319.00Cr as on December 2024 (Q4 24)
Net Profit: ₹589.00Cr as on December 2024 (Q4 24)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis' Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Divis Laboratories Ltd
What is Divis Laboratories Ltd price today?
Divis Laboratories Ltd share price today stands at ₹5640, Open: ₹5750, Previous Close: ₹5754, High: ₹5798, Low: ₹5596, 52 Week High: ₹6285.45, 52 Week Low: ₹3641.
How to Buy Divis Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Divis Laboratories Ltd shares
What are today's traded volumes of Divis Laboratories Ltd?
Today's traded volume of Divis Laboratories Ltd(DIVISLAB) is 5.32L.
What is today's market capitalisation of Divis Laboratories Ltd?
Today's market capitalisation of Divis Laboratories Ltd(DIVISLAB) is ₹149724.28Cr.
What is the 52 Week High and Low Range of Divis Laboratories Ltd?
How much percentage Divis Laboratories Ltd is down from its 52 Week High?
Divis Laboratories Ltd (DIVISLAB) share price is ₹5640. It is down -10.27% from its 52 Week High price of ₹6285.45
How much percentage Divis Laboratories Ltd is up from its 52 Week low?
Divis Laboratories Ltd (DIVISLAB) share price is ₹5640. It is up 54.90% from its 52 Week Low price of ₹3641